Name | Number of supported studies | Average coverage | |
---|---|---|---|
epithelial cell | 3 studies | 20% ± 3% |
Insufficient scRNA-seq data for expression of SPRTN at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 536.60 | 1445 / 1445 | 100% | 10.17 | 183 / 183 |
breast | 100% | 571.06 | 459 / 459 | 100% | 10.86 | 1115 / 1118 |
brain | 100% | 331.67 | 2631 / 2642 | 100% | 8.19 | 705 / 705 |
ovary | 100% | 391.06 | 180 / 180 | 100% | 7.41 | 428 / 430 |
lung | 99% | 418.41 | 575 / 578 | 100% | 9.00 | 1154 / 1155 |
intestine | 100% | 504.43 | 966 / 966 | 99% | 6.62 | 522 / 527 |
uterus | 100% | 511.94 | 170 / 170 | 99% | 8.24 | 454 / 459 |
bladder | 100% | 440.43 | 21 / 21 | 98% | 6.64 | 495 / 504 |
stomach | 100% | 393.19 | 358 / 359 | 98% | 7.07 | 281 / 286 |
thymus | 100% | 515.97 | 652 / 653 | 97% | 5.34 | 587 / 605 |
pancreas | 98% | 232.30 | 323 / 328 | 98% | 5.56 | 175 / 178 |
skin | 100% | 691.83 | 1809 / 1809 | 96% | 8.35 | 453 / 472 |
prostate | 100% | 426.24 | 245 / 245 | 95% | 4.98 | 479 / 502 |
adrenal gland | 100% | 503.63 | 258 / 258 | 91% | 4.90 | 210 / 230 |
kidney | 100% | 354.78 | 89 / 89 | 89% | 4.44 | 802 / 901 |
liver | 100% | 285.64 | 226 / 226 | 87% | 3.86 | 352 / 406 |
adipose | 100% | 573.17 | 1204 / 1204 | 0% | 0 | 0 / 0 |
muscle | 100% | 762.06 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 552.38 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 5.73 | 1 / 1 |
blood vessel | 100% | 387.64 | 1331 / 1335 | 0% | 0 | 0 / 0 |
heart | 99% | 341.37 | 851 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 98% | 8.95 | 44 / 45 |
lymph node | 0% | 0 | 0 / 0 | 93% | 5.37 | 27 / 29 |
peripheral blood | 81% | 300.41 | 756 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 65% | 2.84 | 52 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0036297 | Biological process | interstrand cross-link repair |
GO_0016540 | Biological process | protein autoprocessing |
GO_0006974 | Biological process | DNA damage response |
GO_0009411 | Biological process | response to UV |
GO_0106300 | Biological process | protein-DNA covalent cross-linking repair |
GO_0006508 | Biological process | proteolysis |
GO_0031398 | Biological process | positive regulation of protein ubiquitination |
GO_0019985 | Biological process | translesion synthesis |
GO_0016607 | Cellular component | nuclear speck |
GO_0005654 | Cellular component | nucleoplasm |
GO_0000785 | Cellular component | chromatin |
GO_0005634 | Cellular component | nucleus |
GO_0070530 | Molecular function | K63-linked polyubiquitin modification-dependent protein binding |
GO_0003697 | Molecular function | single-stranded DNA binding |
GO_0003690 | Molecular function | double-stranded DNA binding |
GO_0046872 | Molecular function | metal ion binding |
GO_0004222 | Molecular function | metalloendopeptidase activity |
GO_0031593 | Molecular function | polyubiquitin modification-dependent protein binding |
GO_0005515 | Molecular function | protein binding |
GO_0043130 | Molecular function | ubiquitin binding |
Gene name | SPRTN |
Protein name | DNA-dependent metalloprotease SPRTN (EC 3.4.24.-) (DNA damage protein targeting VCP) (DVC1) (Protein with SprT-like domain at the N terminus) (Spartan) SprT-like N-terminal domain |
Synonyms | C1orf124 DVC1 UNQ1880/PRO4323 |
Description | FUNCTION: DNA-dependent metalloendopeptidase that mediates the proteolytic cleavage of covalent DNA-protein cross-links (DPCs) during DNA synthesis, thereby playing a key role in maintaining genomic integrity . DPCs are highly toxic DNA lesions that interfere with essential chromatin transactions, such as replication and transcription, and which are induced by reactive agents, such as UV light or formaldehyde . Associates with the DNA replication machinery and specifically removes DPCs during DNA synthesis . Catalyzes proteolytic cleavage of the HMCES DNA-protein cross-link following unfolding by the BRIP1/FANCJ helicase . Acts as a pleiotropic protease for DNA-binding proteins cross-linked with DNA, such as TOP1, TOP2A, histones H3 and H4 . Mediates degradation of DPCs that are not ubiquitinated, while it is not able to degrade ubiquitinated DPCs (By similarity). SPRTN activation requires polymerase collision with DPCs followed by helicase bypass of DPCs (By similarity). Involved in recruitment of VCP/p97 to sites of DNA damage . Also acts as an activator of CHEK1 during normal DNA replication by mediating proteolytic cleavage of CHEK1, thereby promoting CHEK1 removal from chromatin and subsequent activation . Does not activate CHEK1 in response to DNA damage . May also act as a 'reader' of ubiquitinated PCNA: recruited to sites of UV damage and interacts with ubiquitinated PCNA and RAD18, the E3 ubiquitin ligase that monoubiquitinates PCNA . Facilitates chromatin association of RAD18 and is required for efficient PCNA monoubiquitination, promoting a feed-forward loop to enhance PCNA ubiquitination and translesion DNA synthesis . . |
Accessions | Q9H040 ENST00000008440.9 [Q9H040-3] ENST00000295050.12 [Q9H040-1] ENST00000391858.8 [Q9H040-2] B1AKT1 ENST00000366644.3 |